This is VyraMed:
Our Story and Evolution

we work for a better future:

Our goal is to bring knowledge, data & support to the healthcare industry. With over 50 years of combined experience in the field, we use our technical & medical expertise to bring forward impactful results.

VyraMed is a product of FetTech.

Purple puzzle pieces forming a square, with one piece separated. This signifies how VyraMed's MTP (Multi-Tissue Platform) is adaptable and can be used in conjunction with other therapies

Adaptable

Can be used in conjunction with other therapies

Purple head silhouette with cross symbol. This signifies how VyraMed's MTP (Multi-Tissue Platform) is safe and has been used clinically on thousands of patients with no reported adverse events.

Safe

The MTP Platform technology has been used clinically on thousands of patients with no reported adverse events 

Purple leaf icon on white background. This signifies how VyraMed's MTP (Multi-Tissue Platform) is natural and is made only of natural components

Natural

Made only of natural components

discover the unlimited potential!

  • Person applying lotion on arm with lavender background. This demonstrates Vyramed's single and clean topical gel (MTPgel aka MTP Gel) application.

    topical gel application

    Future products can be used for localized viral infections like cold sores, rashes and shingles.

    Topical gel antiviral application is simple: clean the affected area, use a clean applicator or finger, apply a thin layer, and gently rub it in.

  • A hand with an intravenous catheter. This signifies VyraMed's INTRAVENOUS APPLICATION. Future products can be applied for the treatment of HIV, hepatitis, rubella, and Rabies.

    Intravenous Application

    Future products can be applied for the treatment of HIV, hepatitis, rubella, and Rabies.

    Intravenous administration of antivirals involves delivering the product directly into the bloodstream for rapid onset of action against bloodborne viruses.

  • Person spraying cleaning solution. This signifies VyraMed's future HOUSE DISINFECTANT APPLICATION which works through mechanisms such as protein denaturation, lipid envelope disruption, oxidative damage to genetic material, or blocking attachment

    House Disinfectant application

    Future products can be applied in household disinfectants to deactivate viruses on treated surfaces.

    Household disinfectants work through mechanisms such as protein denaturation, lipid envelope disruption, oxidative damage to genetic material, or blocking viral attachment to surfaces.

  • Person using nasal spray. This signifies VyraMed's future NASAL SPRAY APPLICATION which can be delivered into the nasal passages for anti-viral applications related to Influenza, Coronavirus, MERS, SARS. Antiviral

    nasal spray application

    Future products can be delivered into the nasal passages for anti-viral applications related to Influenza, Coronavirus, MERS, SARS.

    Antiviral nasal sprays inactivate viral particles in the nasal passages, reducing viral infection and/or spread.

  • Child using a nebulizer with a mask which signifies VyraMed's future NEBULIZER APPLICATION to treat viruses like influenza and coronavirus. This turn liquids into a fine mist for inhalation to target and inhibit respiratory viruses.

    Nebulizer Application

    Future products can be used in nebulizer applications to treat viruses like influenza and coronavirus.

    Nebulizers turn liquids into a fine mist for inhalation, effectively reaching the respiratory tract to target and inhibit respiratory viruses.

  • Black and white image of a person using eye drops. This signifies VyraMed's future EYE DROPS APPLICATION which can be used to treat ocular infections caused by herpes simplex virus (HSV).

    eye drops application

    Future products can be used to treat ocular infections caused by herpes simplex virus (HSV).

    Antiviral eye drops inactivate viruses within the eye, treating viral eye infections.

  • Stethoscope on a purple clipboard with papers. This signifies that Vyramed's MTP technology (aka Multi-Tissue Platform) can be used in conjunction with other therapies and encourages others to join as a development partner.

    other applications

    Our innovative antiviral can be used in conjunction with other therapies.

    Do you want to be part of the driving force of unleashing new opportunities?

    Join us as a development partner and set the scene for the future of antivirals.

our story

Early in the development of our first regenerative medicine product, we discovered that the Multi-Tissue Platform (MTP) had anti-viral activity against enveloped viruses. 

Purple dotted line connecting a circle to a flag shows a timelines of VyraMed's development. We discovered that the Multi-Tissue Platform had anti-viral activity against enveloped viruses which has led to the development of different MTP technology

During the pandemic we refocused our efforts on exploring the antiviral nature of our technology. 

This has led to the development of different forms of the MTP technology, such as a powder, gel, and liquid; which all maintained the anti-viral activity. 

We continue to research the anti-viral nature of the MTP technology and we’re excited to share our results and progress!

Co-founders of VyraMed and FetTech, Clay and Danielle Fette, smiling with a green background and the FetTech logo.

2013 - the beginning of Fettech

Danielle and Clay embarked on their journey with a vision to enhance and expand medical knowledge and innovation.

Close-up of a purple pipette dispensing liquid into a row of clear microcentrifuge tubes in a lab setting. This signifies VyraMed's 2015 discovery: during development of our MTP technology, we discovered it has anti-viral activity.

2015 - VyraMed discovery

During development of our MTP technology, we discovered it has anti-viral activity.

Person in protective suit and gas mask standing on asphalt with yellow grid lines. This signifies that in 2019, the COVID-19 pandemic emerged, increasing VyraMed's focus and priority on development efforts for anti-viral applications.

2019 - Pandemic begins

The COVID-19 pandemic emerged, increasing our focus and priority on development efforts for anti-viral applications.

Person using a microscope in a laboratory setting. Signifying in 2020, VyraMed's test results demonstrated the efficacy of the MTP technology against a wide variety of enveloped viruses, including herpes, HIV, West Nile, poxviruses, coronavirus +

2020 - MTP technology expanded anti-viral test data

Test results demonstrate efficacy of the MTP technology against a wide variety of enveloped viruses, including herpes, HIV, West Nile, poxviruses, coronavirus, influenza, hepatitis, rubella, and rabies.

Group of scientists in lab coats examining a bottle near a microscope in a laboratory setting. This signifies VyraMed's revolutionary breakthrough in anti-viral applications in 2023.

2023 - a revolutionary breakthrough in anti-viral applications

Coming soon!